2021 EAPC/ESC共识文件:个体化运动处方在高血压防治中的应用

2021-03-24 欧洲心脏病学会 Eur J Prev Cardiol . 2021 Mar 24;

2021年3月,欧洲预防心脏病协会(EAPC)联合欧洲心脏病学会(ESC)高血压委员会共同发布了个体化运动处方在肺动脉高压防治中的应用共识文件。高血压及其并发症的治疗仍充满挑战,本文主要针对高血压患者

中文标题:

2021 EAPC/ESC共识文件:个体化运动处方在高血压防治中的应用

英文标题:

Personalized exercise prescription in the prevention and treatment of arterial hypertension: a Consensus Document from the European Association of Preventive Cardiology (EAPC) and the ESC Council on Hypertension

发布机构:

欧洲心脏病学会

发布日期:

2021-03-24

简要介绍:

2021年3月,欧洲预防心脏病协会(EAPC)联合欧洲心脏病学会(ESC)高血压委员会共同发布了个体化运动处方在肺动脉高压防治中的应用共识文件。高血压及其并发症的治疗仍充满挑战,本文主要针对高血压患者的运动处方提供循证指导。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=2021 EAPC_ESC共识文件:个体化运动处方在高血压防治中的应用.pdf)] GetToolGuiderByIdResponse(projectId=1, id=381161c0020e6156, title=2021 EAPC/ESC共识文件:个体化运动处方在高血压防治中的应用, enTitle=Personalized exercise prescription in the prevention and treatment of arterial hypertension: a Consensus Document from the European Association of Preventive Cardiology (EAPC) and the ESC Council on Hypertension, guiderFrom=Eur J Prev Cardiol . 2021 Mar 24;, authorId=0, author=, summary=2021年3月,欧洲预防心脏病协会(EAPC)联合欧洲心脏病学会(ESC)高血压委员会共同发布了个体化运动处方在肺动脉高压防治中的应用共识文件。高血压及其并发症的治疗仍充满挑战,本文主要针对高血压患者, cover=https://img.medsci.cn/2021330/1617114716219_2020535.jpg, journalId=0, articlesId=null, associationId=62, associationName=欧洲心脏病学会, associationIntro=是目前在欧洲居于首要地位的心脏病学会,会员超过70000人、提供更新指南、调查数据、组织学术会议,ESC年会是心血管领域最大的会议。下设5个分会(超声心动图学会、心律学会、心衰学会、预防与康复学会及介入学会)。提供指南较全面,按年份排列。现提供有手机板本。, copyright=0, guiderPublishedTime=Wed Mar 24 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年3月,欧洲预防心脏病协会(EAPC)联合欧洲心脏病学会(ESC)高血压委员会共同发布了个体化运动处方在肺动脉高压防治中的应用共识文件。高血压及其并发症的治疗仍充满挑战,本文主要针对高血压患者的运动处方提供循证指导。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=274, tagName=高血压)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=274, guiderKeyword=高血压, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5150, appHits=234, showAppHits=0, pcHits=929, showPcHits=4915, likes=0, shares=21, comments=12, approvalStatus=1, publishedTime=Tue Mar 30 23:50:47 CST 2021, publishedTimeString=2021-03-24, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Tue Mar 30 22:32:02 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 09:36:25 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 EAPC_ESC共识文件:个体化运动处方在高血压防治中的应用.pdf)])
2021 EAPC_ESC共识文件:个体化运动处方在高血压防治中的应用.pdf
下载请点击:
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1080700, encodeId=6c691080e00e1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53376402115, createdName=ms4000000889797598, createdTime=Thu Dec 16 11:13:05 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076490, encodeId=287e10e649060, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=051b5623088, createdName=ms6000001506539899, createdTime=Fri Dec 03 10:11:51 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055944, encodeId=cbed105594421, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Wed Sep 29 08:57:15 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977868, encodeId=282d9e7868f9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210708/bf9e13628a7540c8bdded17349a84dcd/7595f30ec58b494c9ad54fa09af51de8.jpg, createdBy=3c925261712, createdName=李曌, createdTime=Tue Jun 29 11:21:58 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973420, encodeId=fd879e34205b, content=学习学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7f35520495, createdName=ruipiero, createdTime=Mon Jun 14 11:25:03 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
    2021-12-16 ms4000000889797598

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1080700, encodeId=6c691080e00e1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53376402115, createdName=ms4000000889797598, createdTime=Thu Dec 16 11:13:05 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076490, encodeId=287e10e649060, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=051b5623088, createdName=ms6000001506539899, createdTime=Fri Dec 03 10:11:51 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055944, encodeId=cbed105594421, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Wed Sep 29 08:57:15 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977868, encodeId=282d9e7868f9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210708/bf9e13628a7540c8bdded17349a84dcd/7595f30ec58b494c9ad54fa09af51de8.jpg, createdBy=3c925261712, createdName=李曌, createdTime=Tue Jun 29 11:21:58 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973420, encodeId=fd879e34205b, content=学习学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7f35520495, createdName=ruipiero, createdTime=Mon Jun 14 11:25:03 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
    2021-12-03 ms6000001506539899

    感谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1080700, encodeId=6c691080e00e1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53376402115, createdName=ms4000000889797598, createdTime=Thu Dec 16 11:13:05 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076490, encodeId=287e10e649060, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=051b5623088, createdName=ms6000001506539899, createdTime=Fri Dec 03 10:11:51 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055944, encodeId=cbed105594421, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Wed Sep 29 08:57:15 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977868, encodeId=282d9e7868f9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210708/bf9e13628a7540c8bdded17349a84dcd/7595f30ec58b494c9ad54fa09af51de8.jpg, createdBy=3c925261712, createdName=李曌, createdTime=Tue Jun 29 11:21:58 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973420, encodeId=fd879e34205b, content=学习学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7f35520495, createdName=ruipiero, createdTime=Mon Jun 14 11:25:03 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
    2021-09-29 H8888888

    感谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1080700, encodeId=6c691080e00e1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53376402115, createdName=ms4000000889797598, createdTime=Thu Dec 16 11:13:05 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076490, encodeId=287e10e649060, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=051b5623088, createdName=ms6000001506539899, createdTime=Fri Dec 03 10:11:51 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055944, encodeId=cbed105594421, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Wed Sep 29 08:57:15 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977868, encodeId=282d9e7868f9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210708/bf9e13628a7540c8bdded17349a84dcd/7595f30ec58b494c9ad54fa09af51de8.jpg, createdBy=3c925261712, createdName=李曌, createdTime=Tue Jun 29 11:21:58 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973420, encodeId=fd879e34205b, content=学习学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7f35520495, createdName=ruipiero, createdTime=Mon Jun 14 11:25:03 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
    2021-06-29 李曌

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1080700, encodeId=6c691080e00e1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53376402115, createdName=ms4000000889797598, createdTime=Thu Dec 16 11:13:05 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076490, encodeId=287e10e649060, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=051b5623088, createdName=ms6000001506539899, createdTime=Fri Dec 03 10:11:51 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055944, encodeId=cbed105594421, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Wed Sep 29 08:57:15 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977868, encodeId=282d9e7868f9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210708/bf9e13628a7540c8bdded17349a84dcd/7595f30ec58b494c9ad54fa09af51de8.jpg, createdBy=3c925261712, createdName=李曌, createdTime=Tue Jun 29 11:21:58 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973420, encodeId=fd879e34205b, content=学习学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7f35520495, createdName=ruipiero, createdTime=Mon Jun 14 11:25:03 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
    2021-06-14 ruipiero

    学习学习了

    0

拓展阅读

2009ESH 欧洲高血压指南重新评估

欧洲高血压学会(ESH,European Society of Hypertension) · 2009-11-01

2010 台湾高血压管理指南(英文版)

台湾心脏病学会(TSOC,Taiwan Society of Cardiology) · 2010-01-01

2010年中国肺高血压诊治指南

中华医学会心血管病学分会(Chinese Society of Cardiology) · 2010-01-01

2010高血压患者胆固醇管理临床指导建议

中国心血管相关专家小组(统称) · 2010-02-01

2009年基层版《中国高血压防治指南》

中华人民共和国卫生部(MINISTRY OF HEALTH OF THE PEOPLE`S REPUBLIC OF CHINA) · 2010-02-10

2010 中国急诊高血压管理专家共识

中国医师协会急诊医师分会(CHINESE COLLEGE OF EMERGENCY PHYSICANS,CCEP) · 2010-03-19